Novo Nordisk Beats Q3 Sales and Profit Expectations, Raises 2026 Guidance
J.P. Morgan analysts say Novo Nordisk’s consensus earnings expectations are likely to rise around 3% after the drugmaker reported third-quarter sales 8% above expectations and operating profit 12% above expectations, and upgraded its 2026 guidance.
Novo Nordisk consensus earnings expectations are likely to rise by around 3% after the Danish drugmaker reported stronger than expected third-quarter results and upgraded 2026 guidance, J.P.Morgan analysts write. Novo's sales beat by 8% while operating profit beat by 12%, driven by outperformance a…